Neurodegenerative disorders such as Alzheimer’s or Parkinson’s disease, can be difficult to pin down. They are often not diagnosed until late stages if ever, making them difficult to treat. NeuroFlex® provides objective measures of brain performance, which are scientifically linked to specific disorders and thus, help you assess the status of your patient’s brain health with confidence.
Brain Health in Ageing
Why choose NeuroFlex®
Objective, quantitative
measurements
Typically, diagnosis of neurological problems is based primarily on behaviors and experiences. Patient reports are subjective and may change from day to day. While this information is vital to proper care, it is prone to errors.
We provide accurate, objective measurements of brain function health to help healthcare professionals fill in the gaps and provide a higher standard of care.
Track progress over time
As with diagnosis, progress is difficult to quantify. “I think I feel better” is not a reliable indicator of recovery.
With NeuroFlex®, clinicians can measure assess the effect of treatment exactly and observe effects in real time, which means that patients get better treatment more quickly.
Manage personalized
treatment plans
With the ability to track your patients over time, you can adjust their treatment protocols with real data on their rate of improvement.
Be a part of the new standard of care and start using NeuroFlex® in your clinic today.
Based on scientific expertise
NeuroFlex® is the product of over 60 years of experience in eye and head movement analysis. Mimi Galiana, our Chief Scientific Officer, is a leading expert in the field, with over 200 publications on the subject in top peer reviewed journals. When you go with NeuroFlex®, you know you’re backed by expertise.
Interested in the scientific basis?
Resources:
1. Bueno, A. P. A., J. R. Sato, and M. Hornberger. “Eye tracking–The overlooked method to measure cognition in neuro degeneration?.” Neuropsychologia 133 (2019): 107191.
2. MacAskill, Michael R., and Tim J. Anderson. “Eye movements in neurodegenerative diseases.” Current opinion in neurology29.1 (2016): 61-68.
3. Anderson, Tim J., and Michael R. MacAskill. “Eye movements in patients with neurodegenerative disorders.” Nature Reviews Neurology 9.2 (2013): 74-85.
4. Rodríguez Labrada, Roberto, Yaimeé Vázquez Mojena, and Luis Velázquez Pérez. “Eye movement abnormalities in neuro degenerative diseases.” Eye Motility (2019).
5. Pa, Judy, et al. “The functional oculomotor network and saccadic cognitive control in healthy elders.” Neuroimage 95 (2014): 61-68.
6. Lage, Carmen, et al. “Distinctive oculomotor behaviors in Alzheimer’s disease and frontotemporal dementia.” Frontiers in aging neuroscience 12 (2021): 525